APLM logo

Apollomics Inc. Class A Ordinary Shares


APLM: Apollomics Inc is an innovative clinical-stage biotechnology company. It is is focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. It has a pipeline of 9 drug candidates across multiple programs, 6 of which are in the clinical stage of development.


Show APLM Financials

Consumer Interest
SEC Filings

Recent trades of APLM by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by APLM's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Anti pd-1 antibodies Jan. 24, 2023
  • Patent Title: Anti pd-l1 antibodies Sep. 07, 2021
  • Patent Title: Anti pd-1 antibodies Apr. 20, 2021
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of APLM in WallStreetBets Daily Discussion


Recent insights relating to APLM

CNBC Recommendations

Recent picks made for APLM stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in APLM

Corporate Flights

Flights by private jets registered to APLM